MBTPS1 and inflammatory bowel disease: In this context, S1P pathway is now emerging as a promising target for human IBD treatment [289] since its pharmacological modulation leads to the internalization of S1PR1 receptors in lymphocytes, preventing their mobilization from lymph nodes.